# Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct05462496/  
OnCo record `nct05462496` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fOLFIRINOX / mFOLFIRINOX and pembrolizumab in pancreatic cancer, run by Icahn School of Medicine at Mount Sinai, now recruiting.

## Summary

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT05462496 by Icahn School of Medicine at Mount Sinai, with a registry enrolment figure of 25 participants, started 2023-03-16 and due to reach its primary completion in 2027-08. Interventions recorded: Biopsy; FOLFIRINOX; Ciprofloxacin; Metronidazole; Pembrolizumab; Surgical Resection. Conditions listed: Pancreatic Cancer. Primary outcome: Achievement of overall immune response; Achievement of overall immune response. Pancreatic eligibility wording from the registry: "* Histologically confirmed pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT05462496
- Phase: 2
- Setting: Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Neoadjuvant Checkpoint-based Immunotherapy Following Chemotherapy in Pancreatic Adenocarcinoma
- Sponsor: Icahn School of Medicine at Mount Sinai
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT05462496: https://clinicaltrials.gov/study/NCT05462496

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05462496.json